Axsome Therapeutics, Inc.
AXSM
주식 순위
#2366
Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to... Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depression. This compound is also in Phase III clinical evaluation for Alzheimer's disease agitation and has successfully finished Phase II trials investigating its use for smoking cessation. AXS-07, a novel, orally administered, rapidly-acting investigational medicine that employs multiple mechanisms of action. It has concluded two Phase III studies for the acute treatment of migraine attacks. AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is presently undergoing a Phase III trial for narcolepsy. AXS-14, an oral investigational drug, advancing through Phase III trials for the management of fibromyalgia. Axsome Therapeutics also engages in a research collaboration with Duke University to further assess AXS-05's potential in smoking cessation. The company, established in 2012, has its main offices in New York, New York.
주가
$159.65
마지막 동기화: 2026-10-20
시가총액
$8.36B
변동 (1일)
2.46%
변동 (1년)
21.51%
국가
US
거래 Axsome Therapeutics, Inc. (AXSM)
카테고리
Healthcare
Axsome Therapeutics, Inc. (AXSM)의 발행 주식 수
June 2026 기준 발행 주식 수: 51.50M
Axsome Therapeutics, Inc.의 최신 재무 보고서와 주가에 따르면 현재 발행 주식 수는 51.50M입니다. December 2023 말 기준 회사는 45.43M주를 발행했습니다. 발행 주식 수는 일반적으로 주식 분할이나 자사주 매입에 의해 영향을 받습니다.
Axsome Therapeutics, Inc. (AXSM)의 발행 주식 수 기록 (2013 ~ 2026)
매년 말 기준 발행 주식 수
| 연도 | 발행 주식 수 | 변화 |
|---|---|---|
| 2026 (TTM) | 51.50M | 7.49% |
| 2024 | 47.91M | 5.48% |
| 2023 | 45.43M | 11.73% |
| 2022 | 40.66M | 8.07% |
| 2021 | 37.62M | 1.11% |
| 2020 | 37.21M | 9.37% |
| 2019 | 34.02M | 26.55% |
| 2018 | 26.88M | 18.09% |
| 2017 | 22.76M | 18.87% |
| 2016 | 19.15M | 60.32% |
| 2015 | 11.95M | -6.08% |
| 2014 | 12.72M | 62.59% |
| 2013 | 7.82M | 0.00% |
유사 기업 또는 경쟁사의 발행 주식 수
| 회사 | 발행 주식 수 | 차이 | 국가 |
|---|---|---|---|
| 253.90M | 393.00% |
US
|
|
| 396.00M | 668.92% |
US
|
|
| 478.91M | 829.91% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | 20.75% |
NL
|
